# Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan

> **NCT05402020** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 17018 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium (Tio)
- **DRUG:** Inhaled corticosteroids (ICS)
- **DRUG:** Olodaterol (Olo)
- **DRUG:** Long-acting β2-agonists (LABA)

## Key facts

- **NCT ID:** NCT05402020
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-30
- **Primary completion:** 2023-02-13
- **Final completion:** 2023-02-13
- **Target enrollment:** 17018 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05402020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05402020, "Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05402020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*